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Recent studies have reported that alleles in the premutation range in the FMR1 gene inmales result in increased
FMR1 mRNA levels and at the same time mildly reduced FMR1 protein levels. Some elderly males with
premutations exhibit an unique neurodegenerative syndrome characterized by progressive intention tremor and
ataxia. We describe neurohistological, biochemical and molecular studies of the brains of mice with an
expanded CGG repeat and report elevated Fmr1mRNA levels and intranuclear inclusions with ubiquitin, Hsp40
and the 20S catalytic core complex of the proteasome as constituents. An increase was observed of both the
number and the size of the inclusions during the course of life, which correlateswith the progressive character of
the cerebellar tremor/ataxia syndrome in humans. The observations in expanded-repeat mice support a direct
role of the Fmr1 gene, by either CGG expansion per se or by mRNA level, in the formation of the inclusions and
suggest a correlation between the presence of intranuclear inclusions in distinct regions of the brain and the
clinical features in symptomatic premutation carriers. This mouse model will facilitate the possibilities to
perform studies at the molecular level from onset of symptoms until the final stage of the disease.
INTRODUCTION
Fragile X syndrome, the most common inherited form of mental
retardation, is almost exclusively caused by an expansion of a
CGG repeat in the 50 untranslated region of the FMR1 gene. In
the normal population, the CGG repeat is polymorphic and
ranges from 5 to 50 CGGs with an average length of 30 CGG
units (1). Fragile X patients have>200 CGG units (full mutation)
that are usually hypermethylated and the methylation extends
to the adjacent promoter region of FMR1 (2–4). The gene
is transcriptionally silenced and the gene product, the fragile X
mental retardation protein (FMRP), is absent. The lack of FMRP
in neurons is the cause of the mental retardation in fragile X
patients (5,6). Unmethylated expansions of 50–200 CGG units,
called premutations, are found in both males and females and
may grow to a full mutation only upon maternal transmission to
the next generation. The risk of transition is dependent on the size
of the premutation and the smallest CGG repeat number known
to expand to a full mutation is 59 repeats (7).
Individuals with a premutation were initially thought to have
no phenotypic manifestations; however, a number of studies
have reported mild learning disabilities and emotional
problems in a small subgroup of premutation carriers (8). In
addition, 20% of female premutation carriers manifest pre-
mature ovarian failure (POF) (9). Interestingly, recent studies
have reported individuals with alleles in the premutation range
*To whom correspondence should be addressed at: CBG-Dept of Clinical Genetics, Erasmus MC, PO Box 1738, 3000 DR Rotterdam, The Netherlands.
Tel: þ31 104087198; Fax: þ31 104089489; Email: b.oostra@erasmusmc.nl
{The authors wish it to be known that, in their opinion, the first two authors should be known as joint First Authors.
Human Molecular Genetics, 2003, Vol. 12, No. 9 949–959
DOI: 10.1093/hmg/ddg114
Human Molecular Genetics, Vol. 12, No. 9 # Oxford University Press 2003; all rights reserved
with increased FMR1 mRNA levels that are up to 8-fold higher
than normal and mildly reduced FMRP levels (10–12). Several
studies have hypothesized that lengthened CGG repeats in the
50 UTR lead to the translational impediment of the FMR1
message and consequent FMRP reduction (10,12,13). The
question whether these elevated FMR1 mRNA levels and
reduced FMRP levels result in a mild fragile X phenotype may
need to be revisited by the recent description of older males
carrying a premutation, who exhibit an unique neurodegenera-
tive syndrome characterized by progressive intention tremor
and ataxia. More advanced cases are accompanied by memory
and executive function deficits, anxiety and eventual dementia
(14,15). MRI studies (T2 signal) of the brain of symptomatic
adult male premutation carriers showed a characteristic
imaging, including hyperintensities of the middle cerebellar
peduncle, cerebellar white matter lateral, superior and inferior
to the dentate nuclei and volume loss involving the pons,
mesencephalon, cerebellar cortex, cerebral cortex, white matter
of the cerebral hemispheres and corpus callosum (16).
Neurohistological studies on the brains of four symptomatic
elderly premutation carriers demonstrated neuronal degenera-
tion in the cerebellum and the presence of eosinophilic
intranuclear inclusions in both neurons and astroglia.
Furthermore, the inclusions showed a positive reaction with
anti-ubiquitin antibodies, which suggests a link with the
proteasome degradation pathway (17). The origin and cons-
titution of the inclusions is poorly understood; however,
elevated FMR1 mRNA levels have been proposed to be
important for the formation of the inclusions (15).
To better understand the timing and mechanism involved in
FMR1 CGG repeat instability and methylation, we originally
generated a mouse model in which the endogenous mouse
CGG repeat was replaced by a human CGG repeat carrying 98
CGG units, which is in the premutation range (18). The
‘knock-in’ CGG triplet mouse shows moderate CGG repeat
instability upon both maternal and paternal transmission. The
recent clinical and molecular findings that premutation alleles
may contribute to a specific tremor/ataxia syndrome in older
males prompted us to further analyse the aging ‘knock-in’
CGG triplet mouse. Here we describe neurohistological,
biochemical and molecular studies of the brains of these mice
and report elevated Fmr1 mRNA levels and intranuclear
inclusions with ubiquitin, Hsp40 and the 20S catalytic core
complex of the proteasome as constituents.
RESULTS
Quantification of Fmr1 mRNA and Fmrp
We have analysed the expression of the Fmr1 gene at the RNA
and protein level in the expanded-repeat mice. The transcrip-
tional activity of the Fmr1 gene was determined by quantitative
measurement of Fmr1 mRNA levels using the fluorescence-
based RT–PCR approach. The basis of this method is the
accurate determination in the increase in Fmr1-specific
amplicon during the early cycles of the PCR reaction. The
level of Fmr1 mRNA in expanded-repeat mice compared with
control mice is determined using the expression of GUS
mRNA in both mice as an internal control as is described by
Tassone et al. (10). Figure 1 illustrates the relative Fmr1
mRNA levels in brain tissue for the CGG expanded-repeat
mice at different ages (1–72 weeks). It is evident from the data
in Figure 1 that the Fmr1 transcript levels were elevated and
displayed ratios increased 2–3.5-fold relative to wild-type (wt)
brain tissue. We have plotted only the data from the mice that
were also used for immunohistochemistry; however, more mice
at ages intermediate to the ones above were used for the
quantification of Fmr1 mRNA levels, and displayed elevated
levels. In addition, for each individual mouse the exact length
of the CGG repeat in tail DNA was determined (Fig. 1).
The level of FMRP is thought to be within the normal range in
males with a premutation (6), although in premutation carriers
with a higher number of repeats a decrease in FMRP levels has
been described (10,12). To examine in mice the relationship
between increased Fmr1 mRNA levels and Fmrp levels we
determined Fmrp levels in brain homogenates from expanded-
repeat mice using quantitative immuno-precipitation (IP) and
western blotting. If elevated Fmr1 mRNA levels were positively
correlated with Fmrp levels we would expect to see increased
Fmrp levels. However, Figure 2 shows no obvious decrease in
Fmrp levels in brain immunoprecipitates from a 72- and
30-week-old expanded-repeat mouse compared with wt mice
(72 weeks old). No Fmrp was detected in the supernatants after
IP (data not shown). Western blot analysis of total protein
extracts with anti-actin antibodies shows that equivalent
amounts of protein from the individual mice were used for the IP.
Immunohistochemistry and neuropathology
The brains of the different expanded-repeat mice were cut via
the saggital suture and embedded in paraffin with the medial
side downwards. Gross examination revealed no obvious
Figure 1. Relative Fmr1 RNA levels by real-time fluorescent RT–PCR of brain
of expanded-repeat mice compared with wild-type brain at age 1–72 weeks.
The repeat length is determined of tail DNA at 10 days by the fragile X size
polymorphism assay.
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abnormalities compared with wild-type mice, including overall
brain volume. Haematoxylin and eosin (H/E) stained saggital
sections from the different expanded-repeat mice were
examined for the presence of eosinophilic inclusions, as has
been described for brain tissue of premutation males (17).
Haematoxylin, a basic dye, binds to acidic components of a
tissue (e.g. DNA and RNA) and gives a blue colour, while
eosin, an acidic dye, binds to basic components of a tissue (e.g.
cytoplasmic proteins) and gives a red colour. With this routine
staining protocol we could not observe eosinophilic inclusions
in the different expanded-repeat mice (20–72 weeks, data not
shown). Further microscopic examination revealed no evident
neuropathological phenomena, including neuronal cell loss,
gliosis, astrocytosis (GFAP staining) and axonal torpedos.
Since H/E staining revealed absence of inclusions we used as
a next step to identify inclusions an immunocytochemical
staining for ubiquitin, a hallmark for inclusions in neurons of
affected premutation males. Three different antibodies directed
against ubiquitin were used and all showed the presence of
ubiquitin-positive inclusion bodies in neuronal nuclei. The
results of monoclonal antibody FK1 is depicted in Figure 3A
and B, illustrating the presence of poly-ubiquitinylated-positive
inclusions in the nuclei of the parafascicular thalamic nucleus.
The ubiquitin-positive inclusions could be observed only in
nuclei of neurons throughout the brain, although very rarely a
cytoplasmic inclusion could be observed (data not shown).
Interestingly, each positively stained nucleus contained only a
single inclusion. We have not observed nuclear inclusion in
astrocytes, oligodendrocytes or microglial cells in any of the
mice. Sections analysed from both wild-type and Fmr1
knockout mice reveal a low level of cytoplasmic labelling
with no evidence of intranuclear inclusions.
The average size of the inclusions within one specific brain
region varied between the different expanded-repeat mice. In
younger mice, smaller sized inclusions were present compared
to older mice. Statistical analysis of the surface area of the
inclusions in nuclei from the parafascicular thalamic nucleus
between a 30 (mean 1.2 mm2, SD 0.5) and 72-week-old (mean
3.5 mm2, SD 1.0) expanded-repeat mouse revealed a highly
significant difference (P< 0.001; t-test).
A comprehensive quantitative evaluation for the presence of
ubiquitin-positive inclusions in the different paraffin embedded
brain regions of five mice (20–72 weeks) is shown in Table 1.
This systematic analysis demonstrates the presence of high
percentages (>25%) of inclusions in specific brain structures,
including olfactory nucleus, parafascicular thalamic nucleus,
medial mammillary nucleus and colliculus inferior. Moderate
percentages (10–25%) of inclusions were observed in the
frontal cortex, pontine nucleus, vestibular nucleus and the tenth
cerebellar lobule. In areas with high percentages of inclusions,
the surface area of the inclusions tended to be larger compared
with brain structures with low or moderate percentages of
inclusions. Notably, it cannot be excluded that, due to our
sampling and analysis method, some small brain areas with a
relative high number of neurons with intranuclear inclusions
have not been identified. We have used an alternative method to
demonstrate the presence of ubiquitin-positive inclusions in
brain tissue using frozen material instead of paraffin material.
Cryostat sections from a 74-week-old expanded-repeat mouse
showed similar results (data not shown).
Further research was focused on the constitution of the
inclusions using an extensive panel of monoclonal and
polyclonal antibodies directed against FMRP, proteins related
to FMRP and proteins known to be involved in other disorders
with inclusion formation (see Materials and Methods).
Immunolabeling with antibodies against FMRP showed
patterns of immunoreactivity seen in control animals, but
failed to immunostain inclusions in brain areas known to
contain high percentages of ubiquitin-positive intranuclear
inclusions. An example is given in Figure 3C illustrating Fmrp
distribution in the inferior colliculus (dorsal cortex) of a
72-week-old expanded-repeat mouse. As is described in Table
1, we find approximately half of the neurons with intranuclear
inclusions. All the nuclei of the inferior colliculus (Fig. 3C) and
other brain regions were totally devoid of Fmrp-positive
inclusions. Fmrp distribution and quantity in the cell body of
neurons of the expanded-repeat mouse appeared similar to
wild-type mouse (compare Figure 3C and D), with the caveat
that immunocytochemical analysis only allows semi-
quantitative assessments. This similarity in quantity is in line
with the data for Fmrp levels shown in Figure 2.
Immunolabelling of brain sections from a 72-week-old
expanded-repeat mouse with other antibodies of the panel
showed the presence of both Hsp40 (data not shown) and the
Figure 2. Western blot analysis of immunoprecipitated protein brain extracts
from wild-type mice, 72 weeks (lane 1) and CGG expanded-repeat mice, 72
weeks (lane 2) and 30 weeks (lane 3). (A) immunoprecipitation with rabbit anti-
bodies against FMRP followed by western blot analysis with monoclonal anti-
bodies against FMRP. (B) Western blot analysis of total protein extracts with
anti-actin antibody.
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Figure 3. Immunohistochemical localization of ubiquitin in the parafascicular thalamic nucleus from the expanded-repeat mouse at the age of 72 weeks by an
indirect immunoperoxidase technique (A and B). Note the presence of intranuclear ubiquitin-positive inclusions in approximately half of the nuclei at low mag-
nification (A). The neurons in the inferior colliculus of both the expanded-repeat mouse (C; 72 weeks) and wild-type mouse (D) show almost similar levels of
FMRP expression using monoclonal antibodies against FMRP. Colocalization of ubiquitin (E) and 20S proteasome (F) is shown in a neuron from the frontal cortex
of the expanded-repeat mouse (72 weeks) using double-labelling immunofluorescence. Merge of the two signals demonstrates a clear colocalization of ubiquitin
and the 20S proteasome within the intranuclear inclusions (G). Colocalization of ubiquitin (H) and ethidiumbromide staining for total RNA (I) in a neuron from the
parafascicular thalamic nucleus of the expanded-repeat mouse (72 weeks) using immunofluorescence. Overlay of the two signals demonstrates that ethidium-
bromide staining does not localize to ubiquitin-positive intranuclear inclusions (J). Magnifications: (A) 50; (B) 400; (C and D) 150; (E–J) 700.
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20S catalytic core complex of the proteasome within a
significant number of inclusions (Fig. 3E–G). Simultaneous
labelling of ubiquitin (Fig. 3E, red) and the 20S complex
(Fig. 3F, green) in a neuron of the frontal cortex revealed a clear
co-localization (Fig. 3G, merge). We have tested antibodies
against a number of proteins related to FMRP and proteins
known to be involved in other disorders involving inclusion
bodies: FXR1P, FXR2P, ribosomal P antigen, MAP2, tyrosine-
tubulin, MAP1B, actin, SUMO-1, prion protein, neurofilament,
GFAP, TAU, nucleolin, presinilin 1, a synuclein, Hsp70,
Hsp60, Hsp27, Hsp72 and beta A4. All the antibodies
displayed a specific labelling pattern in the brain, however,
positive-labelled inclusions were not detected. In addition we
tested the 1C2 antibody, which specifically recognizes
pathogenic polyglutamine expansions in CAG expanded-repeat
diseases (19). No specific labelling was seen in wild-type and
expanded-repeat mice.
Microscopic visualization of DNA and total RNA was
achieved by DAPI and ethidiumbromide staining, respectively.
To study whether Fmr1 transcripts or other RNA/DNA
constituents were present within the inclusions a double
labelling has been performed with ethidiumbromide (total
RNA) staining (Fig. 3I, red) followed by immunoincubation
with antibodies against ubiquitin (Fig. 3H, green). No
co-localization could be observed (Fig. 3J, merge). A similar
experiment using DAPI (DNA) staining after immunoincuba-
tion with antibodies against ubiquitin also showed no
co-localization (data not shown), although due to the non-
specific nature of this test, we cannot rule out a small
accumulation of RNA within the inclusions.
A dramatic age-dependent somatic instability was reported in
a transgenic mouse model for DM1 (20). We asked whether
somatic instability coincides with the occurrence of inclusion
bodies in the neurons. For each individual mouse the exact
length of the CGG repeat was determined in tail DNA 10 days
after birth (Fig. 1). We have observed somatic instability, but
the increase in repeat length was never more than 10 repeats.
An example is shown in Figure 4. The original repeat length of
102 CGGs in tail DNA at 10 days of age increased in week 52
to 104 CGGs in brain. The repeat was more unstable in kidney
and testis with a mosaic pattern between 102 and 109 CGGs at
52 weeks of age.
DISCUSSION
Molecular findings
The mechanisms of CGG repeat instability is still poorly
understood and attempts to generate transgenic mouse models
with unstable CGG repeats were successful only very recently
(18,21). Unfortunately, the inheritance of the CGG repeat is
only moderately unstable, indicating differences between the
behaviour of the Fmr1 premutation CGG expanded-repeat in
mouse and in human transmissions. Nevertheless, our data
using a transgenic CGG expanded-repeat mouse model shows,
as in humans, 2–3.5-fold elevated Fmr1 mRNA levels in brain
tissue compared with control. These elevated Fmr1 message
levels were already present in brain homogenates of pups at the
age of 1 week. The increased FMR1 message levels in cells
from males carrying a premutation are intriguing and several
mechanisms have been proposed. Tassone et al. (10) suggest
that the elevated FMR1 mRNA levels are due to increased
transcriptional activity as compensatory mechanism for the
diminished translational efficiency of the FMR1 message,
because no significant increase in FMR1 mRNA stability was
observed. In this hypothetical model the expanded CGG tract
in the 50-UTR of the message diminishes translation by a
currently unknown mechanism. Conformational changes in the
mRNA that influence the initiation of translation and stalled
Table 1. Quantitative analysis of ubiquitin-positive intranuclear inclusions in various brain structures
Brain structures 72 weeks 55 weeks 42 weeks 30 weeks 20 weeks
Nuclei % Nuclei % Nuclei % Nuclei % Nuclei %
Frontal cortex 630/76 12 808/13 2 857/5 <1 1232/1 <1 1012/0 <1
Sensory/motor cortex 1671/52 3 1556/13 1 2025/0 <1 2454/0 <1 1976/0 <1
Cingulate cortex 602/54 9 740/15 2 816/2 <1 906/3 <1 859/0 <1
Visual cortex 508/5 1 953/4 <1 1279/0 <1 1099/1 <1 1190/0 <1
Hippocampus 1315/11 1 1446/5 <1 1056/0 <1 1642/0 <1 858/0 <1
Dentate gyrus 606/0 <1 1199/0 <1 2100/0 <1 1545/0 <1 859/0 <1
Hypothalamus (medial mammillary nucleus) 237/59 25 634/137 22 901/111 12 458/8 2 825/0 <1
Olfactory nucleus (anterior) 622/161 26 1629/108 7 596/28 5 1344/18 1 1092/1 <1
Striatum 506/4 1 1449/5 <1 1505/1 <1 1447/0 <1 929/0 <1
Substantia nigra 357/13 4 615/4 1 1380/2 <1 1184/3 <1 1006/0 <1
Parafascicular thalamic nucleus 1230/524 43 902/107 12 1634/217 13 1290/110 9 1005/0 <1
Colliculus inferior (dorsal cortex) 718/398 55 1184/226 19 1196/115 10 1022/40 4 875/7 1
Colliculus superior 1266/26 2 1395/8 1 1788/5 <1 1272/1 <1 1202/1 <1
Pontine nucleus 414/71 17 604/55 9 720/17 2 872/14 2 988/0 <1
Vestibular nucleus 503/74 15 547/44 8 534/16 3 639/10 2 986/0 <1
Purkinje cell layer 818/1 <1 573/0 <1 ND — 393/0 <1 409/0 <1
Third cerebellar lobule (granular layer) 826/5 1 2188/6 <1 955/0 <1 1843/0 <1 1474/0 <1
Tenth cerebellar lobule (granular layer) 1185/256 22 3314/300 9 ND — 1046/55 5 886/0 <1
Spinal cord (superficial dorsal horn) 1220/285 23 ND — ND — ND — ND —
Spinal cord (deep dorsal horn) 1475/81 5 ND — ND — ND — ND —
Spinal cord (ventral horn) 1137/33 3 ND — ND — ND — ND —
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40S ribosomal subunits are proposed explanations
(10,12,13,22). In addition, the expanded CGG repeat may lead
to proportionally more open promoter conformation and
consequently enhanced transcriptional activity (12). The
normal FMR1 message levels in the mutant I304N cell line
argues against a role for the lack of functional FMRP as
modulator of transcriptional activity of the FMR1 gene (12,22).
Another candidate for the up-regulation of the Fmr1 expression
might be CGGBP1, a CGG binding protein, that has shown to
be able to regulate expression from the FMR1 gene with a
small CGG repeat (23). It can be hypothesized that in the case
of an elongated CGG repeat the CGGBP1 might be sequestered
due to extensive binding to the elongated repeat in the mRNA
resulting in a lowered active concentration of CGGBP1. A
lower CGGBP1 concentration results in an increased FMR1
transcription.
Despite the elevated Fmr1 message in brain tissue of
expanded-repeat mice quantitative immunoprecipitation and
western blotting showed comparable Fmrp levels. In contrast,
cells from males carrying a premutation with elevated levels of
FMR1 message were accompanied by 20% reduced levels of
FMRP in humans with a repeat of 100 CGGs (10,12,24). In the
mouse the reduction in FMRP expression may be more subtle
and below the detection level by the assay, or may differ
between peripheral blood and brain.
For a number of trinucleotide repeat diseases the repeats are
found to be somatically unstable, often varying from tissue to
tissue. It is hypothesized that somatic mosaicism has some
influence on the tissue specificity and the progression of the
symptoms. Also in a number of mouse models, somatic
instability has been seen (25–27) with dramatic instability seen
in mouse models for HD and DM1 (20,28). The highest
somatic instability in the DM1 model was an increase of over
500 repeats. We have tested the somatic instability in the CGG
expanded-repeat mouse. Somatic instability was detected,
although the increase was relatively small (less than 10 units).
From this we conclude that somatic instability in the brain is
not a general phenomenon but it cannot be excluded that it
might play a role in the development of inclusion bodies in
individual neurons.
Immuno-neuropathology
The present immunohistochemical study provides significant
evidence for the presence of ubiquitin-positive intranuclear
inclusions in neurons of the CGG expanded-repeat mouse.
Ubiquitin-positive inclusions associated with CGG repeat
expansions have recently been described in brains of males
carrying a premutation (17). The authors reported the presence
of eosinophilic ubiquitin-positive inclusions in both neuronal
and astrocytic nuclei throughout the cerebrum and brainstem,
but most prominent in the hippocampal formation. The
inability to stain the mouse inclusions with eosin and the
increase in size of the inclusions in time may reflect a
progressive change of the composition of the inclusions. For
the human brain, neuropathology was studied using
post-mortem material; thus, examination was performed at the
final stage of the tremor/ataxia syndrome with pronounced
clinical features. In our expanded-repeat mice neuropathology
was studied between 20 and 72 weeks before pronounced
clinical features were obvious, however, extensive analysis of
the phenotype of the expanded-repeat mice is necessary to
determine both the onset and the development of the tremor/
ataxia syndrome in mice. This study is in progress and will be
addressed by combined MRI imaging and extensive behaviour
studies. Perhaps older expanded-repeat mice (>72 weeks) will
accumulate more aggregation-prone proteins within the inclu-
sions and stain positive for eosin too. Another striking
difference from humans is the absence in the mouse of
astrocytic intranuclear inclusions and other neuropathologic
Figure 4. Somatic mutation analysis by fragile X size polymorphism assay.
(A) Repeat length of tail DNA of an expanded-repeat male mouse was assayed
at 10 days. The length in different tissues was determined again after 52 weeks:
(B) brain; (C) kidney; (D) testis.
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features, including neuronal loss, gliosis and marked dropout of
Purkinje cells. Although the importance of astrocytic inclusions
in man is still not understood, the absence of both astrocytic
inclusions and the aforementioned neuropathology in the
expanded-repeat mouse may reflect differences between
species, like the eosin staining an early onset of the disease.
The origin of the intranuclear inclusions is unknown, however
some characteristics are shared with hereditary ataxias linked to
expansion of CAG repeats. Each of the polyglutamine diseases
is characterized by neuronal intranuclear inclusions that consist
of accumulations of insoluble aggregated polyglutamine-
containing fragments (29). Unlike the hereditary ataxias, the
FMR1 premutation allele gives rise to the production of
normal FMRP because the CGG expansion resides in the 50
UTR of the FMR1 mRNA. This would argue against the
presence of Fmrp in the inclusions, as was demonstrated in the
present study, however we cannot exclude the possibility
that very small quantities of Fmrp, below the detection level
of the immunocytochemical assay, are present in the inclusions.
Alternatively, Fmrp although present, may be inaccessible in the
protein aggregates. Further sophisticated analysis using mass
spectrometry is in progress to address this issue.
The association of elevated FMR1 message levels in
connection with the tremor/ataxia syndrome raises the prob-
ability of the presence of FMR1 transcripts within the
inclusions. We have addressed this issue using double-labelling
techniques in which ubiquitin was stained together with either
ethidiumbromide or DAPI for detection of total RNA and DNA
molecules, respectively (30). The lack of both total RNA and
DNA indicates that they are not major constituents of the
inclusions. The use of riboprobes to pick out single mRNA
molecules are in progress, however to date the results are
inconclusive.
The presence of both ubiquitin and the 20S core complex of
the proteasome within the inclusions is intriguing and suggests a
role of the proteasome degradation pathway in the cause of the
cerebellar tremor/ataxia syndrome. In addition, the presence of
Hsp40 (DnaJ family), a molecular chaperone that promotes
cellular protein folding by binding unfolded polypeptides, within
the inclusions indeed suggests involvement of the proteasome
degradation pathway (31). Again, the presence of components of
the ubiquitin–proteasome pathway is shared with several
hereditary ataxias and other trinucleotide repeat disorders,
including Huntington’s disease (32,33), SCA type 1 (34), SCA
type 3 (35), SCA type 7 (36) and OPMD (37). Whether the
formation of aggregates underlies the clinical symptoms remains
unsolved, and a direct toxic role for aggregates has been
questioned. A model has been proposed in which the
polyglutamine expansion has a toxic gain-of-function property
on the protein, however a direct cause-and-effect relation
between nuclear inclusions and the disease mechanisms is still
under debate (29,38,39). Recent studies of cellular models of
polyglutamine diseases point to impaired proteasome function
in the presence of polyglutamine fragments. The cellular
consequences of perturbation of the ubiquitin–proteasome
degradation pathway in polyglutamine disorders may include
transcriptional dysregulation of important genes, potentially
leading to neuronal cell death (40,41). The model that
aggregation-prone proteins can impede proteasome activity
mediating neuronal dysfunction and death has also been
proposed as a general model for a variety of the neurodegenera-
tive diseases (29). The constitution of the inclusions in post-
mortem brain tissue from males carrying a premutation is now
under study, however, in the present study we have demonstrated
that Fmr1 mRNA and Fmrp are not the major constituents of
the inclusions in mouse. The challenge for the near future is to
identify the aggregation-prone proteins and/or mRNAs within
the inclusions. One group of candidate proteins may include
putative CGG binding proteins trapped by the expanded CGG
Fmr1 transcripts (23,42). Perhaps the long CGG tract in the
mRNA attracts high quantities of CGG binding proteins with
a consequent cumulative cytotoxic effect that may lead to
intranuclear inclusion formation. Such a mechanism has been
described for myotonic dystrophy (DM), where the expanded
CTG repeat containing message is present in small intranuclear
foci, and contributes to the constellation of features that
characterize DM (43). In addition, the mutant RNA attracts high
quantities of CUG binding proteins, which regulate alternative
splicing of the insulin receptor and results in insulin resistance
in myotonic dystrophy (44).
Clinical correlates
The presence of ubiquitin-positive intranuclear inclusions in
neurons of all CGG mice at different ages (20–74 weeks)
provides evidence for a common neuropathological hallmark
associated with Fmr1 premutation alleles. The increase of both
the number and the size of the inclusions during the course of
life correlate with the progressive character of the cerebellar
tremor/ataxia syndrome in humans and suggest that inclusion
formation plays a critical role in the onset and development of
the syndrome.
The main and first presenting symptoms observed in the
group of symptomatic premutation carriers is a progressive
intention tremor and a gait ataxia with loss of balance and a
tendency to fall. These motor disturbances are usually ascribed
to cerebellar dysfunction. However, as in humans, intranuclear
inclusions were absent in Purkinje cells and very limited in the
granular layer, with the exception of lobule 10 in the posterior
cerebellum of the mouse, which showed relatively high
numbers of granule cells with intranuclear inclusions. The
affected part of the cerebellum is also known as the vestibulo-
cerebellum, because of its direct connections with the
vestibular nuclei, which also showed relatively high numbers
of neurons with intranuclear inclusions. Therefore it seems
likely that patients with the cerebellar symptoms like ataxia
with imbalance and the tendency to fall are due for a major part
to dysfunction of the vestibulo-cerebellum and the vestibular
system. Problems with eye movements as suggested by the
mild saccadic pursuit that was found in some patients (14) also
point to involvement of the vestibular nuclei.
Other cerebellar symptoms in the patients, especially the
intention tremor, are usually attributed to the cerebro-
cerebellum, the largest part of the cerebellum, receiving input
from cortical motor areas by way of the pontine nuclei. In our
mice nuclear inclusions were very low in the cerebro-
cerebellum and also appeared low in the cerebellar nuclei
(data not shown). However, the pontine nuclei did show a
relatively high number of cells with intranuclear inclusions as
also described in humans (17). Furthermore, in MRI studies of
Human Molecular Genetics, 2003, Vol. 12, No. 9 955
the patients, a decrease was found in size of the pons and the
medial cerebellar peduncle, which contains the axons project-
ing from the pontine nuclei to the cerebellar cortex (16).
Dysfunction of the pontine nuclei may thus contribute to
disturbed granule cell input and impaired cerebellar function-
ing. It should be noted that, unlike the mouse, there is
substantial Purkinje cell dropout in the cerebellums of the
affected human carriers; that neuropathologic change is likely
to play a prominent role in the clinical findings in humans.
Some of the motor deficits in the patients, like resting tremor
and rigidity, are usually regarded as Parkinson’s disease-like
symptoms and thus attributed to lowered levels of dopamine in
the striatum due to degeneration of dopaminergic cells in the
substantia nigra. However, neither the substantia nigra nor the
striatum showed any nuclear inclusions in our expanded-repeat
mice and were relatively limited in humans (17). Interestingly,
in our expanded-repeat mice we found intranuclear inclusions in
a relatively high number of cells in the posterior part of the
thalamus, which we identified as the parafascicular thalamic
nucleus. This thalamic nucleus has strong connections with the
striatum, rather than with cortical areas as most parts of the
thalamus (45). It has further been suggested that a decrease in
activity in the parafascicular nucleus leads to a decrease in
dopamine release in the striatum (46). Thus the mild Parkinson’s
disease-like symptoms in the patients may be explained
by dysfunction of the parafascicular thalamic nucleus.
With respect to motor functioning it should be added that the
patients lack any signs of muscle weakness or other signs of
higher or lower motoneuron disease. This fits well with the
absence of intranuclear inclusions in motoneuronal nuclei
(although some intranuclear inclusions were observed in the
neuropil of the ventral horn) and the relatively low number of
intranuclear inclusions in the (primary) motor areas. A general
survey of the main cortical areas shows that inclusions occur,
especially in the frontal cortex and in the cingulate cortex,
whereas more posterior parietal and visual areas were much
less affected. These findings are in agreement with findings in
the brain of human adult fragile X premutation carriers,
although in their analysis inclusions were present more or less
equally throughout the cortex (17). Our finding that inclusions
are preferentially located in the frontal and cingulate cortex
would fit with findings that symptomatic adult fragile X
premutation carriers show cognitive and emotional decline.
Memory loss has also been described in these patients and fits
with pathological findings in human patients who show many
affected neurons in the hippocampus. Surprisingly, in the
present study, no pathology was found in the hippocampus or
the dentate gyrus. However, we did find relatively high
numbers of neurons with intranuclear inclusions in the
mammillary bodies. These nuclei, which are part of the
hypothalamus, are strongly involved in memory formation,
especially of recent events both in human (47) and in rat (48).
Whether our mice show memory deficits in behavioural tests is
presently being investigated.
A surprising finding was that the inferior colliculus showed
the highest percentage of cells with nuclear inclusions. Since
all auditory pathways from the cochlea converge onto the
inferior colliculus, impairment of inferior collicular functioning
would lead to hearing problems (49). Interestingly, two of the
five patients described by Hagerman et al. (14) had bilateral
hearing loss at a relatively early age, suggesting that decreased
functioning of the inferior colliculus occurred in these patients.
In conclusion, the observations in expanded-repeat mice
suggest a correlation between the presence of intranuclear
inclusions in distinct regions of the brain and the clinical
features in symptomatic premutation carriers. Moreover, the
presence of inclusions in expanded-repeat mice supports a
direct role of the Fmr1 gene, by either CGG expansion per se
or mRNA level, in the formation of the inclusions, which in
humans could also be explained by a synergistic effect with
another genetic locus. The presence of ubiquitin, 20S
proteasome complex and molecular chaperone Hsp40 within
the intranuclear inclusions strongly indicates perturbation of
normal proteasome degradation pathways in the CGG
expanded-repeat mouse. Thus, inclusion formation seems to
play a crucial role in the development of the tremor/ataxia
syndrome among older males carrying a premutation.
The challenge for the near future is to understand the origin
of the inclusions, their constitution and how dysfunction of the
proteasome is related to the syndrome. Although the frequency
of the tremor/ataxia syndrome among carriers remains to be
established it is now apparent that premutation alleles
contribute to a phenotype at later age. This might be important
for premutation carriers (1 :800) (50) with a repeat size >71
CGG repeats, who have until recently been thought to be
without a clinical phenotype since Greco et al. (17) described a
case with a premutation of 71 CGG repeats in which inclusion
bodies have been found. This mouse model will facilitate the
possibilities to perform studies at the molecular level from
onset of symptoms until the final stage of the disease.
Ultimately, this mouse model might contribute to knowledge
and understanding of how neurons die in a variety of
neurodegenerative diseases, including Alzheimer’s disease,




Mice carrying a human (CGG) repeat (from 102 to 110 units),
varying in age from 1 to 74 weeks old, were sacrificed, and
brain tissue was isolated and cut sagittally into two equal
pieces. One part was immediately frozen in liquid nitrogen for
RNA extraction, and quantitative western blotting. The other
part was immediately fixed in 4% paraformaldehyde for
immunohistochemistry.
The following monoclonal and polyclonal antibodies
were used: rabbit anti-ubiquitin (1:500, DAKO), mouse
anti-ubiquitin (FK1, 1:100 recognize only poly-ubiquitinylated
proteins; FK2, 1:100 recognize both poly- and mono-
ubiquitinylated proteins, both from Affiniti), rabbit anti-FMRP
(51), mouse anti-FXR1P (52), rabbit anti-FXR2P (53), human
anti-ribosomal P antigen (PO, 1:100, Immunovision), mouse
anti-MAP2 (1:100, Boehringer), mouse anti-tyrosine-tubulin
(1 :100, Sigma), mouse anti-MAP1B (1:100, Sigma), mouse
anti-actin (1:100, Sigma), rabbit anti-SUMO-1 (FL-1-101,
1:100, Santa Cruz), goat anti-prion protein (PrP27–30, 1:500,
Chemicon), mouse anti-neurofilament (SMI-32, 1:1000,
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Sternberger monoclonals), mouse anti-GFAP (1:500, DAKO),
mouse anti-TAU (BR01, 1:500, Innogenetics), mouse anti-
nucleolin (C23, 1:100, Santa Cruz), mouse anti-polyglutamine
(1C2, 1:1000, Chemicon), rabbit anti-20S core complex of
the proteasome (54), goat anti-presinilin 1 (C20, 1:100,
Sanvertech), rabbit anti-a synuclein (1:100, Chemicon), rabbit
anti-Hsp70 (1:100, Sanvertech), rabbit anti-Hsp25 (1:100,
Sanvertech), goat anti-Hsp27 (1:100, Sanvertech), rabbit
anti-Hsp40 (1:100, Stressgen), rabbit anti-Hsp60 (1:100,
Stressgen), and mouse anti-Hsp72 (1:100, Amersham), and
mouse anti-beta A4 (1:100 þ90% formic acid, DAKO).
Visualization of the primary antibodies was performed with
rabbit anti-mouse (Ig)/HRP (1:100, DAKO), swine anti-rabbit
(Ig)/HRP (1:100, DAKO), rabbit anti-goat (Ig)/HRP (1:100,
DAKO), goat anti-human (Ig)/HRP (1:100, DAKO), goat
anti-mouse (Ig)/FITC (1:100, Sigma) or goat anti-rabbit/
TRITC (1:100, DAKO).
RNA-isolation and RT–PCR analysis
Brains were homogenized under liquid nitrogen and divided
into two parts for RNA and protein isolation. Total RNA was
isolated from brain by extraction with the single-step acid
phenol method, using RNAzol B (Tel-Test Inc.) and
employed for quantitative fluorescent RT–PCR. Total RNA
was treated with RQ DNase I (Promega) for 30 min at 37C
followed by phenol extraction. The total RNA was analyzed
spectrophotometrically for purity and quantity. The RNA was
stored at 80C until use.
One microgram of total RNA was pre-incubated with 0.6 mg
random hexamers (Pharmacia) and oligo(dT)12–18 (Pharmacia)
at 65C for 10 min. cDNA synthesis was then carried out at
42C for 120 min in a total volume of 25 ml with 180 U SSII-
RT and supplier’s buffer (Invitrogen), 1 mM DTT, 10 U RNase
inhibitor (Invitrogen), 0.8 mM each dNTP. For a quantitative
estimate of the relative Fmr1 mRNA levels, we adapted
the technique described by Tassone et al. (10), using an
ABI7700 Sequence Detector with Applied Biosystems SYBR
Green PCR master mix (P/N 4309155). TheFmr1 amplicon is
a 134 bp product spanning the junction between exons 6 and 7
of the gene (positions 581–715 of GenBank sequence
NM_008031). The following primers were used: forward,
50-CAG TTG GTG CCT TTT CTG TAA CT-30; reverse,
50-GAG ACA ACT TAG TGC GCA GAC T-30. The relativea
bundance of Fmr1 mRNA was assessed by comparison with the
mouse b-gluronidase (GUS) mRNA (GenBank accession
number NM_010368.1) for a 63 bp amplicon detected with
primers: forward, 50-CTG GAG GAT TGC CAA CGA A-30
and; reverse 50 GCT TCC GAA ACA CTG GGT TCT 30. For
each sample there was 1 ml of cDNA added to the master PCR
mix and taken in triplicate and Fmr1 and GUS reactions were
run in parallel. The final reaction volume was 25 ml in the
Applied Biosystems SYBR Green PCR master mix (P/N
4309155) with 5 or 10 mM of each primer. Cycle parameters
were 2 min at 50C and 10 min at 95C, followed by 45 cycles
with 15 s at 95C denaturation and 1 min at 60C annealing/
extension. Relative Fmr1 levels were calculated as follows:
2[DCt(fragile X)7DCt(control)]¼ 2DCt, where DCt equals
Ct(FMR1) Ct(GUS) as discussed in Tassone et al. (10). At the
end of each PCR run, a dissociation curve analysis was performed.
In addition, gel electrophoresis was performed to confirm the
correct size of the amplicon and the absence of non-specific
bands. Each sample was assayed a minimum of two times.
DNA analysis
DNA was extracted from mouse tissue or tail by incubating
with Protein K in 335 ml lysis buffer (10 mM Tris–HCl, 400 mM
NaCl, 2 mM EDTA pH 7.3–7.4, 1% SDS) overnight at 55C
NaCl, 150 ml 6 M, was added and the suspension was
centrifuged. To the supernatant two volumes 96% ethanol were
added to precipitate the DNA. DNA was dissolved in 100 ml
H2O. The fragile X size polymorphism assay (Perkin Elmer
Biosystems) was used to determine the exact length of the
CGG repeat. PCR conditions were as described by the Perkin
Elmer Biosystems. PCR samples were analysed with an
ABI3100 sequencer (PE Biosystems).
Immunoprecipitation (IP) and western blotting
Equal amounts of extracts from mouse brains were incubated at
room temperature for 1 h in a final volume of 0.5 ml of the
protein extraction buffer [10 mM Hepes, 300 mM KCl, 5 mM
MgCl2, 5 mM CaCl2, 0.45% Trition X-100, 0.05% Tween, pH
7.6; protease inhibitor cocktail mix (Roche), containing 50 ml
protein-A-sepharose beads (Amersham)]. The pre-cleared
supernatants were incubated overnight at 4C with antibody
KI, a rabbit polyclonal antibody directed against the C-terminal
part of FMRP, followed by an incubation for 2 h at room
temperature with 50 ml protein-A-sepharose beads.
Subsequently, the beads were extensively washed with the
extraction buffer. The immunoprecipitated proteins were
electrophoresed on a 7.5% SDS–polyacrylamide gel. Ten
percent of protein extracts used for the IP was applied for
direct western blotting. Following SDS–PAGE, proteins were
electroblotted onto a nitrocellulose membrane. Mouse anti-
bodies against FMRP (51) and against a-actin (1:3000, Sigma)
were used as primary antibodies for immunodetection.
Horseradish peroxidase labelled anti-mouse IgG was used as
secondary antibody, allowing chemiluminesce detection with
ECL KIT (Amersham).
Immunohistochemistry
Brain tissues (20-, 30-, 42-, 55- and 72-week-old mice) were
fixed overnight at 4C and embedded sagittally in paraffin
according to standard protocols. Sections (5 mm) were cut,
deparaffinized and hydrated followed by microwave treatment
and subsequent indirect immunoperoxidase labeling for the
antibodies described above. Brain tissue of a 74-week-old
mouse was embedded in Tissue Tek (Miles laboratory)
and frozen in liquid nitrogen for cryostat sections. For a
detailed protocol for both paraffin and cryostat sections see
Bakker et al. (55). Routine histological analysis was
performed on haematoxylin and eosin stained sections. For
quantitative analysis of the number of ubiquitin-positive
nuclear inclusions, each brain (20–72 weeks) was sectioned
from medial to lateral direction and at 50 mm intervals
each section was incubated with anti-ubiquitin antibodies
for comprehensive analysis for the presence of ubiquitin
Human Molecular Genetics, 2003, Vol. 12, No. 9 957
inclusions in the different brain regions. The brain of the
72-week-old mouse was used to identify the brain regions that
showed high numbers of ubiquitin-positive intranuclear
inclusions. In addition, we have included some regions of
interest on the basis of the phenotype described in sympto-
matic premutation carriers (see Table 1). The different regions
were recognized using the mouse brain atlas (56) and the
number of inclusions was expressed as a percentage of the
total number of nuclei examined in that particular brain
region. For double immuno-fluorescence labelling (74-week-
old mouse only), mouse anti-ubiquitin (FK1, Affiniti) was
mixed with rabbit anti-20S proteasome in the first incubation
step, followed by a secondary step with a mixture containing
anti-rabbit conjugated with FITC and anti-mouse conjugated
with TRITC. Visualization of DNA and total cellular RNA
by ethidiumbromide or DAPI in combination with mouse
anti-ubiquitin (FK1, Affiniti) incubation was performed by
using the protocol according to Tang et al. (30). The surface
area of the ubiquitin-positive inclusions were estimated by
using the Leica Image Analysis system.
Brain sections from wild-type and Fmr1 knockout mouse
(both 72 weeks old) were used as a control for the presence and
labeling specificity of both ubiquitin-positive nuclear inclu-
sions and the expression level of Fmrp in neurons.
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